Statistics for 417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors
Total visits
| views | |
|---|---|
| 417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors | 120 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| Durm2020Design-Abstract-CCBYNC.pdf | 194 |
| java.util.UUID:61c67b42-6cce-49c4-b116-f94ccca9e8d0 | 86 |
| java.util.UUID:df958795-8a2d-46a6-86a8-45ed04a92642 | 12 |
| java.util.UUID:f170f603-66d9-4ea8-9093-5c2285e42663 | 6 |
Top country views
| views | |
|---|---|
| United States | 77 |
| China | 10 |
| South Korea | 5 |
| Canada | 3 |
| Iran | 2 |
| Netherlands | 2 |
| Russia | 2 |
| Australia | 1 |
| United Kingdom | 1 |
| Malaysia | 1 |
| Singapore | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 35 |
| Mount Laurel | 8 |
| Fairfield | 7 |
| Houston | 6 |
| San Francisco | 5 |
| Seoul | 4 |
| Beijing | 3 |
| Maastricht | 2 |
| Shanghai | 2 |
| Volgograd | 2 |
| Boston | 1 |
| Cambridge | 1 |
| Daly City | 1 |
| Esfahan | 1 |
| Gangnam-gu | 1 |
| Hefei | 1 |
| Lenox | 1 |
| Minneapolis | 1 |
| Mulgrave | 1 |
| Nanjing | 1 |
| Ottawa | 1 |
| Seattle | 1 |
| Seremban | 1 |
| Singapore | 1 |
| Tehran | 1 |
| Toronto | 1 |
| Vancouver | 1 |
| Washington | 1 |
| White Plains | 1 |